The PRESTO (Prevention of Restenosis with Tranilast and its Outcomes) protocol: A double-blind, placebo-controlled trial-Reference-Cited by-同舟云学术

The PRESTO (Prevention of Restenosis with Tranilast and its Outcomes) protocol: A double-blind, placebo-controlled trial

Published:2000-01 Issue:1 Volume:139 Page:23-31
ISSN:0002-8703
Container-title:American Heart Journal
language:en
Short-container-title:American Heart Journal

Author:

Holmes David,Fitzgerald Peter,Goldberg Sheldon,LaBlanche J-M,Lincoff A.Michael,Savage Michael,Serruys P.W.,Willerson James,Granett Jeffrey R.,Chan Robert,Shusterman Neil H.,Poland Marcia

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference22 articles.

1. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease;Serruys;New Engl J Med,1994

2. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease;Fischman;N Engl J Med,1994

3. Restenosis after successful coronary angioplasty: serial angiographic follow-up of 229 patients;Nobuyoshi;J Am Coll Cardiol,1988

4. Efficacy of coronary stenting vs balloon angioplasty in small coronary arteries;Savage;J Am Coll Cardiol,1998

5. Suppressive effects of tranilast on the expression of inducible cyclooxygenase (COX2) in interleukin-1β-stimulated fibroblasts;Inoue;Biochem Pharmacol,1997

Cited by 64 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unlocking the potential of tranilast: Targeting fibrotic signaling pathways for therapeutic benefit;International Immunopharmacology;2024-08

2. Highlights of the treatment of allergic rhinitis according to Chinese guidelines;Current Opinion in Allergy & Clinical Immunology;2023-06-20

3. Therapeutic angiogenesis and tissue revascularization in ischemic vascular disease;Journal of Biological Engineering;2023-02-16

4. Inflammasomes as Potential Therapeutic Targets in Atherosclerotic Cardiovascular Disease;Endocrine, Metabolic & Immune Disorders - Drug Targets;2022-12

5. Microchannel-embedded implantable device with fibrosis suppression for prolonged controlled drug delivery;Drug Delivery;2022-02-11